CYSTINOSIS TREATMENT MARKET ANALYSIS

Cystinosis Treatment MarketSize and Trends

Cystinosis Treatment Market Dynamics

Various government grants to support the diagnosis and treatment of cystinosis is boosting growth of the market. For instance, in 2013, the Cystinosis Research Foundation awarded six grants worth US $1.29 million to Cystinosis researchers for developing better treatments and a cure for the disease. Organizations such as Cystinosis Research Network are responsible to spread awareness regarding disease by celebrating Cystinosis Awareness Day on May 7, every year. Furthermore, product approval by the Food and Drug Administration (FDA) is expected to boost growth of the cystinosis treatment market over the forecast period. In 2013, the FDA approved the delayed-release formulation of cysteamine bitartrate (DR-C) for patients aged 6 years and above, and the label was expanded in 2015 to include children age two years. Cysteamine is a cystine-depleting agents that reduces cystine levels in cells. It has proven to be effective in preventing or delaying renal failure and improving growth of children with Cystinosis. In 2013, FDA approved Cystaran (cysteamine ophthalmic solution) for the treatment of corneal cystine crystal accumulation. Treatment with Cystaran should be initiated as soon as cystine crystals are found within the corneas. Lack of focus on R&D due to low prevalence rate and limited treatment options can negatively impact cystinosis treatment.

Cystinosis treatment Market Regional Insights

Regional segmentation of Cystinosis treatment market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is the expected to dominate the cystinosis treatment market. According to an article published by Cystinosis Research Network, an estimated 15 new nephropathic cystinosis cases are diagnosed in the U.S. annually. Moreover, the network also works on increasing awareness about disease among regional population. High prevalence rate of cystinosis in Europe is expected to drive growth of the cystinosis treatment market in the region. According to National Institutes of Health (NIH), cystinosis affects 1 in 26,000 persons in France.